In a major development that could reshape how blood is monitored during surgical procedures, Inspira Technologies has revealed that its HYLA blood sensor achieved 96% accuracy in a key parameter during its most recent clinical study. The device, which uses artificial intelligence to provide continuous, real-time blood monitoring, demonstrated noteworthy reliability in comparison to standard blood test analyzers.
According to the company, the trial took place at Sheba Hospital in Israel—recognized among the world’s top healthcare centers—and involved six patients undergoing open-heart surgery. Placed at two separate points along the blood circuit tubing, the HYLA sensor tracked oxygen levels and other parameters continuously, offering constant measurements without the need for repeated blood draws. “We consider these exceptional results that mark a pivotal milestone in our mission to transform critical care monitoring,” said Dagi Ben-Noon, CEO of Inspira Technologies.
Research findings further underlined the HYLA’s potential to detect indicators for oxygen deficiencies, showing a 92.3% accuracy rate. That level of consistency could be a significant advantage in preventing blood-oxygen deficiency during extended procedures, while reducing time spent on traditional lab tests. Ben-Noon noted, “We believe that achieving 96% accuracy as reflected in our clinical results in real-time blood monitoring without the need for blood draws represents a significant technological breakthrough.”
The achievement arrives on the heels of several other steps forward for Inspira. Earlier this year, through its efforts to roll out first life-support systems, the company introduced its INSPIRA ART100 systems to a leading U.S. hospital. The plan entailed collaborating closely with clinicians for a streamlined integration of the technology into existing protocols. Since then, Inspira has been aligning these systems with HYLA, its AI-enabled sensor platform that harnesses real-time blood data for faster, more targeted clinical decisions.
Beyond progress in respiratory and cardiopulmonary solutions, Inspira’s R&D pipeline also generated headlines with positive results above 95% for preventing bloodstream infections. By using physical electric stimulation rather than chemical agents, the company aims to tackle a major problem in hospital settings: infections linked to intravenous lines. This holistic approach to patient care—spanning from infection prevention to oxygenation accuracy—reflects Inspira’s overarching mission to elevate standards in life-support and diagnostic technologies.
In another previously announced step, Inspira added new support features to its INSPIRA ART100 system. The updated platform includes redesigned alarms and more intuitive on-screen prompts, which potentially reduce staff burden, enhance workflow, and ensure that critical issues are flagged quickly. Integrating these features with the potential real-time data from the HYLA sensor could serve as an all-encompassing resource for healthcare teams managing critical cases.
In the latest study, clinical data was assessed against conventional lab results to validate HYLA’s performance. Traditionally, hospital staff must rely on intermittent blood draws to verify oxygen and carbon dioxide levels, with any deviations requiring additional time between sampling and obtaining results. However, the new AI-powered system automatically measures blood parameters in real time. This proactive approach could be key for early detection of complications—potentially giving surgeons and perfusionists the chance to intervene sooner and more precisely.
With FDA submission planned for the latter half of 2025, Inspira appears intent on widening its portfolio of innovations for both critical care and diagnostic applications. The company foresees placing the HYLA sensor in various critical care environments—ranging from intensive care units to operating rooms—and believes it could eventually extend to emergency medicine. Once authorized in the U.S., the technology will likely see continued clinical data collection and post-market validation, enabling real-time monitoring to become part of routine practice in more hospitals nationwide.
In an industry where even minor improvements can have life-saving consequences, Inspira’s momentum suggests that continuous, AI-driven blood monitoring may become the new standard of care for certain procedures. The combined focus on infection prevention, faster diagnostics, and seamless hospital integrations underscores the company’s broader ambition: to deliver more personalized care while helping clinicians move away from time-consuming and less efficient protocols. If the 96% accuracy reported in this latest study is any indication, HYLA represents a stride in that direction.
Recent News
- Nuvectis Pharma’s NXP900 Shows Promising Efficacy in NSCLC Combination Therapy, Analysts See Significant Upside
- Former Trump Advisor Backs Israeli Innovation to Improve American Food Safety
- Navigating the Shift: Building Resilient Economies in a Post-Globalization World
- Unraveling the Climate Cash: The $7 Billion Controversy Surrounding the Climate United Fund
- G City Europe Reports Strong 2024 Results with Double-Digit Growth in Operational Metrics
Subscribe for More Articles Like This
Nothing in this article constitutes financial or investment advice, nor does it represent an offer to buy or sell securities. This report is published by Wall Street Wire™. The operators of Wall Street Wire are not registered brokers, dealers, or investment advisers. This article contains paid promotional content related to Inspira Technologies and was produced as part of their paid subscription to Wall Street Wire. Inspira Technologies did not review or approve this content prior to publication. Please review the full disclaimers and compensation disclosures here: redditwire.com/terms.